.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Baxter
Covington
Citi
Mallinckrodt
Cerilliant
Federal Trade Commission
Chubb
Harvard Business School
Cantor Fitzgerald

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,008,309

« Back to Dashboard

Which drugs does patent 8,008,309 protect, and when does it expire?


Patent 8,008,309 protects IMBRUVICA and is included in one NDA.

This patent has one hundred and sixteen patent family members in twenty-six countries.

Summary for Patent: 8,008,309

Title:Inhibitors of bruton's tyrosine kinase
Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (San Mateo, CA), Pan; Zhengying (Alpharetta, GA)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:12/499,005
Patent Claim Types:
see list of patent claims
Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,008,309

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,556,182Inhibitors of Bruton's tyrosine kinase► Subscribe
8,754,091Inhibitors of bruton's tyrosine kinase► Subscribe
9,409,911Inhibitors of bruton's tyrosine kinase► Subscribe
8,476,284Inhibitors of Bruton's tyrosine kinase► Subscribe
8,697,711Inhibitors of bruton'S tyrosine kinase► Subscribe
9,127,012Inhibitors of bruton's tyrosine kinase► Subscribe
9,139,591Inhibitors of bruton's tyrosine kinase► Subscribe
8,748,438Inhibitors of Bruton's tyrosine kinase► Subscribe
8,759,516Inhibitors of Bruton's tyrosine kinase► Subscribe
9,181,263Inhibitors of bruton's tyrosine kinase► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,008,309

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
HungaryE031334► Subscribe
China101674834► Subscribe
China101805341► Subscribe
China102746305► Subscribe
China102887900► Subscribe
China103319488► Subscribe
Cyprus1112513► Subscribe
Cyprus1116295► Subscribe
Cyprus1117587► Subscribe
Cyprus1117840► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Federal Trade Commission
UBS
Baxter
Cipla
McKesson
Colorcon
Cantor Fitzgerald
Boehringer Ingelheim
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot